KemPharm Inc. (NASDAQ:KMPH) shares saw unusually-strong trading volume on Tuesday . Approximately 125,626 shares were traded during trading, an increase of 61% from the previous session’s volume of 77,868 shares.The stock last traded at $4.80 and had previously closed at $4.31.

Several analysts have issued reports on KMPH shares. Oppenheimer Holdings Inc. restated a “buy” rating on shares of KemPharm in a research note on Wednesday, June 8th. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th. Zacks Investment Research cut KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Finally, Royal Bank Of Canada dropped their price target on KemPharm from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, May 6th.

The firm has a 50 day moving average price of $4.11 and a 200 day moving average price of $10.33. The company’s market cap is $69.70 million.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. On average, equities analysts predict that KemPharm Inc. will post ($2.44) earnings per share for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.